Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination.
An autopsy case of fatal subacute hepatic failure after administration of troglitazone is described. The liver dysfunction developed about five months after the patient, a sixty-three-year-old woman, had been initially treated with troglitazone. The patient developed hepatic failure and died despite various hepatic auxiliary treatments such as plasmapheresis. Autopsy findings revealed focal liver cell necrosis, cholestasis and steatosis with infiltration of lymphocytes and neutrophils and lack of regenerative activity. The causative mechanism of liver dysfunction may be metabolite aberration, as a result of accumulation of hepatotoxic metabolite(s), in a category of idiosyncratic liver injury. It is proposed to monitor liver function strictly and periodically for the diabetic patients prescribed troglitazone.
Fukano
M
M
Second Department of Internal Medicine, Shiga University of Medical Science, Japan.
Amano
S
S
Sato
J
J
Yamamoto
K
K
Adachi
H
H
Okabe
H
H
Fujiyama
Y
Y
Bamba
T
T
D002839:Chromans / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017093:Liver Failure / Q000139:chemically induced* / Q000473:pathology; D008875:Middle Aged; D009336:Necrosis; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone